Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Hylton

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Radiology|November 1, 1984
Analytical tools for magnetic resonance imagingD A Ortendahl, N Hylton, L Kaufman, et al.
Conference Proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference|February 3, 2007
Quantification of breast tissue index from MR data using fuzzy clusteringC Klifa, J Carballido-Gamio, L Wilmes, et al.
Annals of Surgical Oncology|July 18, 2001
MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancerL Esserman, E Kaplan, S Partridge, et al.
Breast Cancer Research : BCR|June 23, 2025
Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trialRoberto A Leon-Ferre, K Dimitroff, C Yau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2024
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trialL A Huppert, D Wolf, C Yau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2021
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapyL Du, C Yau, L Brown-Swigart, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Radiology|November 1, 1984
Analytical tools for magnetic resonance imagingD A Ortendahl, N Hylton, L Kaufman, et al.
Conference Proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference|February 3, 2007
Quantification of breast tissue index from MR data using fuzzy clusteringC Klifa, J Carballido-Gamio, L Wilmes, et al.
Annals of Surgical Oncology|July 18, 2001
MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancerL Esserman, E Kaplan, S Partridge, et al.
Breast Cancer Research : BCR|June 23, 2025
Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trialRoberto A Leon-Ferre, K Dimitroff, C Yau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2024
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trialL A Huppert, D Wolf, C Yau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2021
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapyL Du, C Yau, L Brown-Swigart, et al.
Pageof 2